

AnteoTech Ltd Managing Director AGM Presentation

BRISBANE, AUSTRALIA, 14 November 2023. AnteoTech Ltd (ASX:ADO) will today present the attached presentation at its Annual General Meeting. A copy of the Managing Director's presentation is attached.

This announcement has been authorised for release by Andrew Cook, Company Secretary.

Media and investor enquiries: Friederike Graser, on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - AnteoTech Ltd (ASX:ADO)

AnteoTech is a revenue stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry, with first revenues targeted for late 2023. The portfolio includes a proprietary high silicon anode in late-stage development, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.









2023 Annual General Meeting Managing Director's Presentation

LEADING THE CHARGE

14 November 2023

COMMERCIAL-IN-CONFIDENCE

This document is the property of AnteoTech Ltd and shall not be communicated to third parties and/or reproduced without prior written agreement. © AnteoTech Ltd 2023



COMMERCIALLY EXPERIENCED LEADERSHIP TEAM



David RadfordManaging Director

- Highly experienced senior executive with a track record of successful commercialisation
 - Former CEO of Nanosonics, General Manager Asia of GE Clinical Systems Services



Friederike GraserDirector Strategic Growth Initiatives

- 12+ years' experience in emerging renewable technologies and energy sector
- Experience in merger and acquisitions, and capital raising programs



Katrina ByrneChief Operating Officer

- Extensive domestic and international multiindustry experience in operations, projects and supply chain management.
- Senior Executive positions leading rapid commercialisation of R&D, Boeing and Rio Tinto



Tsui Min LianChief Marketing Officer

- Experience managing healthcare businesses to grow to become profitable, efficient market leaders
- 17+ years' driving change and transformation with GE, ResMed and Toll Holdings



Andrew CookChief Financial Officer

- 20+ years' experience in senior financial roles focus on energy & renewables
- Track record in leading international teams and negotiating contracts with large corporates including roles at Origin Energy and Energy Queensland



Manuel WieserChief Technology Officer

- 11+ years' experience in Li-ion battery product development and technology commercialisation
- Track record in delivering global commercial partnerships and taking technology from lab-scale to pilot production



FY2023 ACHIEVEMENTS — BUILDING THE FOUNDATIONS FOR GROWTH

Position AnteoTech for short and mid-term revenues in Clean Energy and Life Sciences to create long term value

Commercial Leadership Team

Experienced leadership team focussed on commercial outcomes

Marketing-led sales driven team



Realigned Resources

Reduced cost base and realigned resources into Clean energy

Restructured for a market-led, sales-driven culture



Trinseo – MOU

MOU with global specialty materials solutions provider, Trinseo Europe, to provide for a clear path to a commercial agreement for Anteo X^{TM}



Expanded Capabilities

Strengthened the leadership team

- Tsui Min Lian *Chief Marketing Officer*
- Andrew Cook *Chief Financial Officer*



Capital + Investors

Strengthened balance sheet: \$4.7m Placement & Share Purchase Plan

\$3.8m from R&D rebate

Attracted new institutional investors



Wyon - MOU

Signed MOU for development of silicon anode technology to improve their rechargeable miniature and micro batteries in MedTech

Facility Development

Work commenced on the construction of Anteo X production facility with targeted first production in early Q1-CY24



Anteo X Award Winning

- Renewable Energy category Australian Climate Technology Awards
- Manufacturing Innovation Award Australian Technologies Competition



Growing Pipeline

Showcased Anteo X at The Battery Show Europe 2023 in Stuttgart



- Generated >100 sales leads
- Identified 12 key target relationships



REFOCUSED PRIORITIES – INVESTING FOR HIGH RETURNS

Significant refocus into CET and roles that build value into the business



- 25% reduction in headcount
- **52% reduction** Life Science resources
- **Ceased** point-of-care initiatives
- No expensive clinical studies or regulatory submissions



- **75% increase** in Clean Energy team
- Recruited additional industry expertise
- Reallocation of resources from Life Sciences to Clean Energy



Driving Short-to-mid Term Revenues

- All programs focused upon shortterm revenue growth
- Strategic partnerships focused on delivering revenue in FY24



ANTEOTECH PRODUCTS – INNOVATION DEFINING THE FUTURE

Proven technologies for the rapidly growing battery anode and life science diagnostics markets



Clean Energy Technology

Anteo X™

Anteo X is a performance enhancing additive that reinforces battery binders in silicon containing anodes and improves their performance in next-gen lithium-ion batteries



High Silicon Anode

AnteoTech's **High Silicon Anode**utilises products, formulations and
processes to develop a **proprietary**anode which the Company will **license**to future partners






Life Sciences

AnteoBind™

AnteoBind is a unique product that offers significant productivity gains in the manufacture of diagnostic products





Development Services



FOCUS & EXECUTION THE KEY TO DRIVE REVENUES

Strategies to drive revenues in 2024 — focused on partnering and sales generation with appropriate supporting infrastructure



Clean Energy commercialisation and development activities

Sales and marketing to deliver early commercial revenues and partnerships for Anteo X and anode development programs



Anteo X[™] production facility to meet expected demand

Complete construction and commission our production facility to 20,000 litre annual capacity and beyond



Optimisation & development of High Silicon Anodes

Internal development and customer partnerships driving next generation battery technologies



Commercial activities in Life Sciences focused on revenues

Targeted sales and marketing activities with large Life Science and vaccine manufacturing companies






Enabling the transition to next generation batteries



EARLIER DEVELOPMENT WORK DRIVES LONG-TERM UPTAKE OF ANTEO X™

Early-stage development agreements drive Anteo X annuity sales across the anode development value chain



Development Staging



LEADING THE CHARGE: LEARNINGS FROM EUROPE

Our European counterparties are "marquee brands" and market leaders within their own segments, and acknowledge AnteoTech as a credible business partner



Key Takeaways - European Customer Meetings

- Anode technology and development is lagging
- **↑silicon is a core challenge** 8% to 10% normal
- Integration is a problem lack of expertise
- Data is critical many technologies don't deliver
- Partnering is critical to accelerate development
- Customers willing to pay for access and expertise
- Many startups promise but don't deliver credibility is key



AnteoTech's Value Proposition

- Demonstrated ability to make the transition to higher silicon content (>20%) and drive performance improvements
- Anteo X[™] is enabling the cost-effective development of High Silicon Anodes
- Significantly greater focus upon anodes than most EV companies – expertise and know-how
- Portfolio of results with data to substantiate claims
- High credibility



TARGETED REVENUE OPPORTUNITIES IN THE ANODE VALUE CHAIN

AnteoTech solutions span the anode development process. Estimated sales opportunities >AUD\$1b





PRODUCTION FACILITY TO SUPPORT COMMERCIAL ORDERS

Construction has commenced to support commercial initiatives – Anteo X™ and battery design and testing capabilities

First production facility

- Brisbane-based 20,000L production facility is under construction with commissioning targeted for early Q1-CY24
- Initial cost of \$0.7m nominal incremental cost to move to 40,000L and then 80,000L annual capacity

Anteo X production – Controlling initial product and quality

- Simple chemical production process with minimal labour requirement
- Builds credibility and supports sales initiatives
- Targeting material gross margins

Battery testing capability

 Expansion from 450 batteries on test to 1,000 parallel testing channels





Above: Expansion to battery testing laboratory in progress





Building new revenue opportunities with AnteoBind™



NEW MARKETING APPROACH TO DRIVE GROWTH

Enhanced formulation of AnteoBind™, a targeted sales and marketing approach coupled with a new pricing



Validated AnteoBind Features

- AnteoBind is easier to use vs. conventional chemistry
- Stability of particles for >12months once activated enables batch reproducibility, reduced wastage and processing time
- Reduction in antibodies and labour costs are key differentials
- Safe, non-hazardous achieving highest possible
 ESG standards
- New market for pre-activated particles estimated
 >\$500M AUD



AnteoTech's Value Proposition

- Expansive research and knowledge of particle activation
- AnteoBind enables the creation of a new "particle market" with pre-activated particles
- Reformulation capability decreasing price
- Significant reductions in antibody usage (>30%) and labour(40%)
- Effective across a range of particles lateral flow, enzyme-linked immunoassay and chemiluminescence



COMMERCIALISATION PROGRESS UPDATE FOR CY2024

Leveraging AnteoTech's know-how and key AnteoBind™ benefits to create opportunities for near and mid-term revenues

AnteoBind Go-to-Market Strategy



AnteoBind
Reformulation



Pricing alignment for new target markets

Pricing



Pre-activated particle market AnteoBind Sales/ activation services

Target Marketing



Negotiations currently underway include:

Growth

- Particle manufacturer
- Vaccine manufacturer



DIVERSIFIED SALES MODEL TO MAXIMISE CAPTURE OF TARGET MARKETS

Near-term revenue streams from Proprietary AnteoBind™ Sales and Contract Assay Development Services



Growing commercial footprint & revenue base





LOOKING FORWARD — COMMERCIAL MILESTONES*

2023

- Capital Raise funds growth + new institutions
- Trinseo and Wyon **Anteo X[™] technology validation**
- Construction commences on Anteo X production facility
- Anteo X first commercial revenues EV company
- Commercial agreement Trinseo
- Commercial agreement for AnteoBind™
- Commercial agreement Battery Manufacturer

2024 & Beyond

2024

- Anteo X production commencement
- **Development agreements** EV companies
- Additional Clean Energy partnerships
- Commercial agreement Wyon
- Commercial agreements for AnteoBind
- Anteo X production facility scale up
- **Development partnerships** anode optimisation

2025

• First commercial revenues – High Silicon Anode

^{*}All milestones are estimates and actual timing and events may vary



FUNDING OUR PATHWAY

Reduced costs and refocused resources to higher value opportunities in the clean energy market

Market Cap¹

\$57.1m

Cash + R&D Rebate²

\$7.7m

Debt

Nil

Lower FY24 Cost base³ anticipated ~\$3m _{vs. FY23}

FY24 Y-o-Y Revenue Growth anticipated 100%

R&D Rebate 2023 **\$3.8m**

Shares on issue	2,196 million
Options	142 million
Board & Management	1.4% + Incentive Options
Institutions	~5%
Retail	9,880 shareholders

¹ Closing share price on 10 November 2023

² ASX Quarterly for September 2023 quarter and \$3.77m R&D rebate received 12 October 2023

³ Excluding Depreciation, Amortisation, Share-based Payments and one-off costs



ENVIRONMENTALLY & SOCIALLY RESPONSIBLE

AnteoTech is committed to being a low carbon footprint, sustainable company with the highest possible ESG standards



Quality & Accreditations

Hold ISO 13485 and ISO 9001 accreditations

Production in tier 1 jurisdiction with low sovereign risk and a robust regulatory framework



Advancing Clean Energy Battery Technology

AnteoTech products improve performance of battery technologies, using fewer mined resources, and easy-to-use technologies that do not require high heat or solvents for activation



Eco-Friendly Production and Low Carbon Footprint

Unrefined silicon with lower processing requirement compared to competition

Significant contributor to decarbonisation of battery manufacturing processes



Diagnostics Enabling Life-Saving Medical Interventions

AnteoTech enables point-of-care diagnostics across a range of clinical applications bringing critical decision making to the point of care in medical cases



Cyber Security Protections

AnteoTech has migrated to outsourced model with high quality service vendor

Multi-layer security in place

Cyber security insurance in place



Diversity and Inclusion

Employer of choice

40% Female directors

50% Female executive leadership

>50% of the Company is female

17 Nationalities represented





FIVE KEY TAKEAWAYS



Next Generation Battery Technology

Patent-protected, market-leading, platform technology which unlocks the path to high silicon content battery anodes



Productivity Enhancing Technology

AnteoBind™ enables reduced input costs, antibody and labour costs



Partnering with Industry Leaders – Technology Validated

Multiple international organisations have validated Anteo X^{TM} and AnteoBind



Multiple, Large Revenue Opportunities

Product sales and development revenue opportunities are near term Large volume sales potential for Anteo X and AnteoBind



Building Blocks are in place to Succeed

Commercial leadership team in place with realignment of resources to drive growth